@article{MTMT:34738471,
	title = {ELEVATED SPHINGOSINE 1-PHOSPHATE LEVEL IN FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS},
	url = {https://m2.mtmt.hu/api/publication/34738471},
	author = {Juhász, Lilla and Lőrincz, Hajnalka and Szentpéteri, Anita and Nádró, Bíborka and Varga, E. and Paragh, György and Harangi, M.},
	journal-iso = {ATHEROSCLEROSIS},
	journal = {ATHEROSCLEROSIS},
	volume = {379},
	unique-id = {34738471},
	issn = {0021-9150},
	year = {2023},
	eissn = {1879-1484},
	pages = {S118-S118}
}

@article{MTMT:34732660,
	title = {CORRELATIONS BETWEEN SERUM AFAMIN AND LIPID PARAMETERS IN OBESE TYPE 2 DIABETIC PATIENTS},
	url = {https://m2.mtmt.hu/api/publication/34732660},
	author = {Lőrincz, Hajnalka and Ratku, Balázs and Ötvös, T. and Szentpéteri, Anita and Seres, Ildikó and Paragh, György and Harangi, Mariann and Somodi, Sándor},
	journal-iso = {ATHEROSCLEROSIS},
	journal = {ATHEROSCLEROSIS},
	volume = {379},
	unique-id = {34732660},
	issn = {0021-9150},
	year = {2023},
	eissn = {1879-1484},
	pages = {S104-S104},
	orcid-numbers = {Somodi, Sándor/0000-0002-3615-2300}
}

@article{MTMT:34729478,
	title = {Increased serum PEDF levels and altered lipid profile after renal transplantation in patients with end-stage renal disease},
	url = {https://m2.mtmt.hu/api/publication/34729478},
	author = {Szentimrei, R. and Lőrincz, Hajnalka and Szentpéteri, Anita and Varga, V.E. and Harangi, Mariann and Seres, I. and P. Szabó, Réka and Nemes, Balázs and Paragh, György},
	doi = {10.1016/j.atherosclerosis.2023.06.534},
	journal-iso = {ATHEROSCLEROSIS},
	journal = {ATHEROSCLEROSIS},
	volume = {379},
	unique-id = {34729478},
	issn = {0021-9150},
	year = {2023},
	eissn = {1879-1484},
	pages = {S157-S157}
}

@article{MTMT:34215397,
	title = {Decreased Serum Stromal Cell-Derived Factor-1 in Patients with Familial Hypercholesterolemia and Its Strong Correlation with Lipoprotein Subfractions},
	url = {https://m2.mtmt.hu/api/publication/34215397},
	author = {Juhász, Lilla and Lőrincz, Hajnalka and Szentpéteri, Anita and Tóth, Nóra and Varga, Éva and Paragh, György and Harangi, Mariann},
	doi = {10.3390/ijms242015308},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {24},
	unique-id = {34215397},
	issn = {1661-6596},
	abstract = {Stromal cell-derived factor-1 (SDF-1) is a chemokine that exerts multifaceted roles in atherosclerosis. However, its association with hyperlipidemia is contradictory. To date, serum SDF-1 and its correlations with lipid fractions and subfractions in heterozygous familial hypercholesterolemia (HeFH) have not been investigated. Eighty-one untreated patients with HeFH and 32 healthy control subjects were enrolled in the study. Serum SDF-1, oxidized LDL (oxLDL) and myeloperoxidase (MPO) were determined by ELISA. Lipoprotein subfractions were detected by Lipoprint. We diagnosed FH using the Dutch Lipid Clinic Network criteria. Significantly lower serum SDF-1 was found in HeFH patients compared to healthy controls. Significant negative correlations were detected between serum total cholesterol, triglycerides, LDL-cholesterol (LDL-C), apolipoprotein B100 (ApoB100) and SDF-1. Furthermore, serum SDF-1 negatively correlated with VLDL and IDL, as well as large LDL and large and intermediate HDL subfractions, while there was a positive correlation between mean LDL-size, small HDL and SDF-1. SDF-1 negatively correlated with oxLDL and MPO. A backward stepwise multiple regression analysis showed that the best predictors of serum SDF-1 were VLDL and oxLDL. The strong correlation of SDF-1 with lipid fractions and subfractions highlights the potential common pathways of SDF-1 and lipoprotein metabolism, which supports the role of SDF-1 in atherogenesis.},
	year = {2023},
	eissn = {1422-0067},
	orcid-numbers = {Varga, Éva/0000-0003-2716-0541}
}

@article{MTMT:34214638,
	title = {Assessment of amino-terminal C-type natriuretic peptide serum level and its correlation with high-density lipoprotein structure and function in patients with end stage renal disease before and after kidney transplantation},
	url = {https://m2.mtmt.hu/api/publication/34214638},
	author = {Szentimrei, R. and Lőrincz, Hajnalka and Szentpéteri, Anita and Varga, V.E. and Seres, Ildikó and Varga, Éva and Nemes, Balázs and Harangi, Mariann and Paragh, György},
	doi = {10.1016/j.cbi.2023.110749},
	journal-iso = {CHEM-BIOL INTERACT},
	journal = {CHEMICO-BIOLOGICAL INTERACTIONS},
	volume = {385},
	unique-id = {34214638},
	issn = {0009-2797},
	year = {2023},
	eissn = {1872-7786},
	orcid-numbers = {Varga, Éva/0000-0003-2716-0541}
}

@article{MTMT:34087449,
	title = {520 $aA 2-es típusú cukorbetegségben (T2DM) az inzulinrezisztencia és az elhízás, valamint a kóros lipideltérések között},
	url = {https://m2.mtmt.hu/api/publication/34087449},
	author = {Sztanek, Ferenc and Tóth, László and Molnár, Ágnes and Bak-Csiha, Sára and Szentpéteri, Anita and Lőrincz, Hajnalka and Nagy, Attila Csaba and Paragh, György and Harangi, Mariann},
	journal-iso = {DIABETOLOGIA HUNGARICA},
	journal = {DIABETOLOGIA HUNGARICA},
	volume = {31},
	unique-id = {34087449},
	issn = {1217-372X},
	year = {2023},
	eissn = {2560-0168},
	pages = {71-72},
	orcid-numbers = {Nagy, Attila Csaba/0000-0002-0554-7350}
}

@article{MTMT:34069206,
	title = {Az aerob edzés hatása az oxidatív stressz és az endotheldiszfunkció markereire diabéteszes polyneuropathiás betegekben},
	url = {https://m2.mtmt.hu/api/publication/34069206},
	author = {Molnár, Ágnes and Lőrincz, Hajnalka and Szentpéteri, Anita and Harangi, Mariann and Paragh, György and Sztanek, Ferenc},
	journal-iso = {DIABETOLOGIA HUNGARICA},
	journal = {DIABETOLOGIA HUNGARICA},
	volume = {31},
	unique-id = {34069206},
	issn = {1217-372X},
	year = {2023},
	eissn = {2560-0168},
	pages = {51}
}

@article{MTMT:33204286,
	title = {Effect of semaglutide on lipoprotein subfractions and chemerin levels in type 2 diabetic patients},
	url = {https://m2.mtmt.hu/api/publication/33204286},
	author = {Sztanek, Ferenc and Jakab, Á.A. and Molnár, Ágnes and Szentpéteri, Anita and Lőrincz, H. and Paragh, György and Harangi, Mariann},
	doi = {10.1016/j.atherosclerosis.2022.06.582},
	journal-iso = {ATHEROSCLEROSIS},
	journal = {ATHEROSCLEROSIS},
	volume = {355},
	unique-id = {33204286},
	issn = {0021-9150},
	year = {2022},
	eissn = {1879-1484},
	pages = {120}
}

@article{MTMT:33153228,
	title = {Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis},
	url = {https://m2.mtmt.hu/api/publication/33153228},
	author = {Czókolyová, Monika and Hamar, Attila and Karancsiné Pusztai, Anita and Tajti, Gábor and Végh, Edit and Pethő, Zsófia and Bodnár, Nóra and Horváth, Ágnes and Boglárka, Soós and Szamosi, Szilvia and Szentpéteri, Anita and Seres, Ildikó and Harangi, Mariann and Paragh, György and Kerekes, György and Bodoki, Levente and Katalin, Hodosi and Tamás, Seres and Panyi, György and Szekanecz, Zoltán and Szűcs, Gabriella},
	doi = {10.3390/biom12101483},
	journal-iso = {BIOMOLECULES},
	journal = {BIOMOLECULES},
	volume = {12},
	unique-id = {33153228},
	issn = {2218-273X},
	abstract = {Background: Cardiovascular (CV) morbidity, mortality and metabolic syndrome are associated with rheumatoid arthritis (RA). A recent trial has suggested increased risk of major CV events (MACE) upon the Janus kinase (JAK) inhibitor tofacitinib compared with anti-tumor necrosis factor α (TNF-α) therapy. In our study, we evaluated lipids and other metabolic markers in relation to vascular function and clinical markers in RA patients undergoing one-year tofacitinib therapy. Patients and methods: Thirty RA patients treated with either 5 mg or 10 mg bid tofacitinib were included in a 12-month follow-up study. Various lipids, paraoxonase (PON1), myeloperoxidase (MPO), thrombospondin-1 (TSP-1) and adipokine levels, such as adiponectin, leptin, resistin, adipsin and chemerin were determined. In order to assess flow-mediated vasodilation (FMD), common carotid intima-media thickness (IMT) and arterial pulse-wave velocity (PWV) ultrasonography were performed. Assessments were carried out at baseline, and 6 and 12 months after initiating treatment. Results: One-year tofacitinib therapy significantly increased TC, HDL, LDL, APOA, APOB, leptin, adipsin and TSP-1, while significantly decreasing Lp(a), chemerin, PON1 and MPO levels. TG, lipid indices (TC/HDL and LDL/HDL), adiponectin and resistin showed no significant changes. Numerous associations were found between lipids, adipokines, clinical markers and IMT, FMD and PWV (p < 0.05). Regression analysis suggested, among others, association of BMI with CRP and PWV (p < 0.05). Adipokines variably correlated with age, BMI, CRP, CCP, FMD, IMT and PWV, while MPO, PON1 and TSP-1 variably correlated with age, disease duration, BMI, RF and PWV (p < 0.05). Conclusions: JAK inhibition by tofacitinib exerts balanced effects on lipids and other metabolic markers in RA. Various correlations may exist between metabolic, clinical parameters and vascular pathophysiology during tofacitinib treatment. Complex assessment of lipids, metabolic factors together with clinical parameters and vascular pathophysiology may be utilized in clinical practice to determine and monitor the CV status of patients in relation with clinical response to JAK inhibition.},
	year = {2022},
	eissn = {2218-273X},
	orcid-numbers = {Panyi, György/0000-0001-6227-3301}
}

@article{MTMT:32490017,
	title = {Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology},
	url = {https://m2.mtmt.hu/api/publication/32490017},
	author = {Czókolyová, Monika and Karancsiné Pusztai, Anita and Végh, Edit and Horváth, Ágnes and Szentpéteri, Anita and Hamar, Attila and Szamosi, Szilvia and Hódosi, Katalin and Domján, Andrea and Szántó, Sándor Zoltán and Kerekes, György and Seres, Ildikó and Harangi, Mariann and Paragh, György and Szekanecz, Éva and Szekanecz, Zoltán and Szűcs, Gabriella},
	doi = {10.3390/biom11101535},
	journal-iso = {BIOMOLECULES},
	journal = {BIOMOLECULES},
	volume = {11},
	unique-id = {32490017},
	issn = {2218-273X},
	abstract = {Background: Cardiovascular (CV) morbidity, mortality, and metabolic syndrome are associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Here, lipids and other metabolic markers in relation to vascular function and clinical markers were evaluated in RA and AS patients undergoing one-year anti-TNF therapy. Patients and methods: Fifty-three patients including 36 RA patients treated with either etanercept (ETN) or certolizumab pegol (CZP) and 17 AS patients treated with ETN were included in a 12-month follow-up study. Various lipids, paraoxonase (PON) and arylesterase (ARE) activities, myeloperoxidase (MPO) and adipokine levels were determined overtime. Ultrasonography was performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT), and arterial pulse-wave velocity (PWV) in all patients. All assessments were performed at baseline and 6 and 12 months after treatment initiation. Results: Anti-TNF therapy decreased ARE activity, MPO, adiponectin, and chemerin levels after 12 months (p < 0.05). Lipids, PON activity, and leptin remained unchanged. Regression analyses suggested variable associations of IMT, PWV, and FMD with ARE, MPO, leptin, and lipids (p < 0.05). On the other hand, these metabolic parameters were significantly associated with disease duration, CV history, CRP, obesity, PWV, and IMT (p < 0.05). One-year anti-TNF treatment together with baseline leptin (p = 0.039) or CRP (p = 0.016) levels determined 12 months of lipid changes overtime. TNF inhibition together with baseline disease activity determined ARE activity changes (p = 0.046). Anti TNF therapy and baseline chemerin levels determined IMT changes overtime (p = 0.003). Conclusions: Assessment of various metabolic parameters together with disease activity, CRP, and ultrasound based techniques may exert additional value in determining CV burden and in monitoring the effects of biologics on preclinical vascular pathophysiology.},
	keywords = {LIPIDS; rheumatoid arthritis; Adipokines; ankylosing spondylitis; Biologic therapy; metabolic biomarkers},
	year = {2021},
	eissn = {2218-273X},
	pages = {1-15},
	orcid-numbers = {Szántó, Sándor Zoltán/0000-0001-5030-6292}
}